COSMOS Pharmaceutical Corporation

TSE:3349 Stock Report

Market Cap: JP¥525.4b

COSMOS Pharmaceutical Valuation

Is 3349 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3349 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3349 (¥6521) is trading below our estimate of fair value (¥18147.78)

Significantly Below Fair Value: 3349 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3349?

Key metric: As 3349 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3349. This is calculated by dividing 3349's market cap by their current earnings.
What is 3349's PE Ratio?
PE Ratio19.8x
EarningsJP¥26.09b
Market CapJP¥525.40b

Price to Earnings Ratio vs Peers

How does 3349's PE Ratio compare to its peers?

The above table shows the PE ratio for 3349 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17x
7649 Sugi HoldingsLtd
18x6.9%JP¥450.6b
9989 SundrugLtd
15.7x5.9%JP¥460.5b
3141 Welcia Holdings
18.1x6.4%JP¥398.9b
3391 Tsuruha Holdings
16.2x9.1%JP¥401.8b
3349 COSMOS Pharmaceutical
19.8x5.6%JP¥525.4b

Price-To-Earnings vs Peers: 3349 is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (17x).

Price to Earnings Ratio vs Industry

How does 3349's PE Ratio compare vs other companies in the JP Consumer Retailing Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
3349 19.8xIndustry Avg. 12.5xNo. of Companies21PE0816243240+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3349 is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the JP Consumer Retailing industry average (12.5x).

Price to Earnings Ratio vs Fair Ratio

What is 3349's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3349 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.8x
Fair PE Ratio18.1x

Price-To-Earnings vs Fair Ratio: 3349 is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3349 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥6,521.00
JP¥8,173.57
+25.3%
12.7%JP¥10,000.00JP¥6,650.00n/a14
Dec ’25JP¥7,385.00
JP¥8,222.86
+11.3%
12.9%JP¥10,000.00JP¥6,650.00n/a14
Nov ’25JP¥7,125.00
JP¥8,187.14
+14.9%
13.0%JP¥10,000.00JP¥6,650.00n/a14
Oct ’25JP¥7,348.00
JP¥7,660.38
+4.3%
22.4%JP¥9,750.00JP¥3,325.00n/a13
Sep ’25JP¥7,140.00
JP¥7,553.85
+5.8%
23.1%JP¥9,750.00JP¥3,325.00n/a13
Aug ’25JP¥6,910.00
JP¥7,918.75
+14.6%
16.6%JP¥9,750.00JP¥5,600.00n/a12
Jul ’25JP¥6,475.00
JP¥7,942.08
+22.7%
15.8%JP¥9,500.00JP¥5,600.00n/a12
Jun ’25JP¥6,345.00
JP¥8,260.00
+30.2%
13.6%JP¥10,000.00JP¥6,500.00n/a12
May ’25JP¥7,282.50
JP¥8,301.67
+14.0%
12.8%JP¥10,000.00JP¥6,550.00n/a12
Apr ’25JP¥6,950.00
JP¥8,309.58
+19.6%
12.4%JP¥10,000.00JP¥6,550.00n/a12
Mar ’25JP¥7,242.50
JP¥8,460.45
+16.8%
11.8%JP¥10,000.00JP¥6,550.00n/a11
Feb ’25JP¥7,980.00
JP¥8,505.42
+6.6%
11.3%JP¥10,000.00JP¥6,550.00n/a12
Jan ’25JP¥8,142.50
JP¥8,447.50
+3.7%
11.5%JP¥10,000.00JP¥6,550.00n/a12
Dec ’24JP¥7,907.50
JP¥8,266.82
+4.5%
10.8%JP¥9,500.00JP¥6,550.00JP¥7,385.0011
Nov ’24JP¥7,820.00
JP¥8,266.82
+5.7%
10.8%JP¥9,500.00JP¥6,550.00JP¥7,125.0011
Oct ’24JP¥7,647.50
JP¥8,370.00
+9.4%
11.2%JP¥9,500.00JP¥6,550.00JP¥7,348.0010
Sep ’24JP¥8,567.50
JP¥7,875.00
-8.1%
11.1%JP¥9,000.00JP¥6,550.00JP¥7,140.0012
Aug ’24JP¥8,242.50
JP¥7,875.00
-4.5%
11.1%JP¥9,000.00JP¥6,550.00JP¥6,910.0012
Jul ’24JP¥7,285.00
JP¥7,531.82
+3.4%
10.5%JP¥9,000.00JP¥6,250.00JP¥6,475.0011
Jun ’24JP¥6,770.00
JP¥7,381.82
+9.0%
10.9%JP¥9,000.00JP¥6,250.00JP¥6,345.0011
May ’24JP¥6,845.00
JP¥7,240.91
+5.8%
11.4%JP¥9,000.00JP¥6,250.00JP¥7,282.5011
Apr ’24JP¥5,960.00
JP¥7,359.09
+23.5%
11.7%JP¥9,500.00JP¥6,500.00JP¥6,950.0011
Mar ’24JP¥6,080.00
JP¥7,631.82
+25.5%
12.0%JP¥9,500.00JP¥6,500.00JP¥7,242.5011
Feb ’24JP¥6,375.00
JP¥7,727.27
+21.2%
11.2%JP¥9,500.00JP¥6,500.00JP¥7,980.0011
Jan ’24JP¥6,670.00
JP¥7,981.82
+19.7%
11.6%JP¥9,500.00JP¥6,500.00JP¥8,142.5011
Dec ’23JP¥7,035.00
JP¥7,972.73
+13.3%
11.1%JP¥9,500.00JP¥6,500.00JP¥7,907.5011

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 09:14
End of Day Share Price 2024/12/19 00:00
Earnings2024/08/31
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

COSMOS Pharmaceutical Corporation is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arashi NishizawaBofA Global Research
Mitsuru TakayanagiCitigroup Inc
Jun KawaharaDaiwa Securities Co. Ltd.